Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -2290.88% is 36% below its 5-year average of -1681.23%, around the middle of its 5-year range (-6838.37%–-261.60%).
341.06% below its 12-month average of -519.41%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -507.96%.
EBITDA MARGIN
-2290.88%
EBITDA MARGIN AVG TTM
-519.41%
EBITDA MARGIN AVG 3Y
-1965.16%
EBITDA MARGIN AVG 5Y
-1681.23%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-341.06%
CURRENT VS 3Y AVG
-16.57%
CURRENT VS 5Y AVG
-36.26%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Rani Therapeutics Holdings, Inc.
Market Cap
$54.14M
EBITDA Margin
-2290.88%
TTM Avg
-519.41%
3Y Avg
-1965.16%
5Y Avg
-1681.23%
Market Cap
$52.83M
EBITDA Margin
-40.55%
TTM Avg
-30.41%
3Y Avg
-34.23%
5Y Avg
-32.87%
Market Cap
$52.60M
EBITDA Margin
-36.35%
TTM Avg
-7.28%
3Y Avg
12.63%
5Y Avg
16.49%
Market Cap
$51.99M
EBITDA Margin
-36.23%
TTM Avg
-36.23%
3Y Avg
-36.23%
5Y Avg
-36.23%
Market Cap
$51.88M
EBITDA Margin
-5927.25%
TTM Avg
-3470.39%
3Y Avg
-2050.54%
5Y Avg
-1465.25%
Market Cap
$57.01M
EBITDA Margin
-89640.62%
TTM Avg
-44862.17%
3Y Avg
-44862.17%
5Y Avg
-44862.17%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Rani Therapeutics Holdings, Inc. (RANI) | $54.14M | -2290.88% | -519.41% | -1965.16% | -1681.23% |
| NOMAD Power Solutions, Inc. (NMAD)vs › | $53.70M | N/A | N/A | N/A | N/A |
| Aldeyra The (ALDX)vs › | $55.25M | N/A | N/A | N/A | N/A |
| Spectral AI, Inc. (MDAI)vs › | $52.83M | -40.55% | -30.41% | -34.23% | -32.87% |
| Zhengye Biotechnology Holding Limited (ZYBT)vs › | $52.60M | -36.35% | -7.28% | 12.63% | 16.49% |
| OKYO Pharma Limited (OKYO)vs › | $56.02M | N/A | N/A | N/A | N/A |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $51.99M | -36.23% | -36.23% | -36.23% | -36.23% |
| ImageneBio Inc (IMA)vs › | $51.88M | -5927.25% | -3470.39% | -2050.54% | -1465.25% |
| Connect Biopharma Holdings Limited (CNTB)vs › | $57.01M | -89640.62% | -44862.17% | -44862.17% | -44862.17% |
| eXoZymes, Inc. (EXOZ)vs › | $51.23M | N/A | N/A | N/A | N/A |
Gross Margin
44.9%
EBITDA Margin
-2290.9%
Operating Margin
-2346.0%
Net Margin
-618.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -507.96% |
| 2026-03-31 | -478.81% |
| 2025-12-31 | -571.46% |
| 2025-03-31 | -6838.37% |
| 2024-12-31 | -1429.18% |
| 2021-06-30 | -261.60% |
| 2021-03-31 | -669.58% |
| 2020-12-31 | -2286.67% |
| 2020-09-30 | -2484.26% |
| 2020-06-30 | -5400.00% |
| 2020-03-31 | -6302.41% |
